TY - JOUR
T1 - Utilization and Treatment Patterns of Disease-Modifying Therapy in Pediatric Patients with Multiple Sclerosis in the United States
AU - Greenberg, Benjamin
AU - Kolodny, Scott
AU - Wang, Mengru
AU - Deshpande, Chinmay
N1 - Funding Information:
Financial Disclosures: Dr Greenberg has received grant funding from Chugai, MedImmune, MedDay, Genentech, the National Multiple Sclerosis Society, the Patient-Centered Outcomes Research Institute, the Transverse Myelitis Association, and the Guthy-Jackson Charitable Foundation; has received consulting fees from EMD Serono, Novartis, Alexion, and Chugai; and is on the board of the Transverse Myelitis Association. Dr Kolodny was an employee of Novartis Pharmaceuticals Corp at the time of manuscript acceptance. Dr Chinmay Deshpande is an employee of Novartis Pharmaceuticals Corp. Mr Wang is an employee of KMK Consulting Inc and worked as a consultant for Novartis Pharmaceuticals Corp.
Funding Information:
The authors acknowledge Sirish Cholasamudram (Novartis Healthcare Pvt Ltd) for providing support for writing the manuscript.
Funding Information:
Funding/Support: This study was supported by Novartis Pharmaceuticals Corp.
Publisher Copyright:
© 2021 Consortium of Multiple Sclerosis Centers
PY - 2021/5
Y1 - 2021/5
N2 - Background: The current landscape and treatment patterns of disease-modifying therapy (DMT) use in pediatric patients with multiple sclerosis (MS) are not yet well understood. This study examined DMT utilization and treatment patterns in pediatric patients newly diagnosed as having MS. Methods: Pediatric patients (<18 years old) with two MS diagnosis claims from January 1, 2010, to December 31, 2016, were identified from the MarketScan Commercial Database. The index date was defined as the date of first MS diagnosis, and patients were followed up for 1 year post-index date. Outcomes evaluated included percentage of patients who initiated treatment after MS diagnosis, different DMTs initiated, treatment discontinuation, and switching treatment during follow-up. Results: Of 182,057 patients newly diagnosed as having MS, 288 pediatric patients (mean age, 14 years; 61% female) were identified. Within the first year of diagnosis, 188 patients (65.3%) did not receive any DMT. The most common first-initiated treatments were interferons and glatiramer acetate (83%), but 28% of patients switched or discontinued from first-initiated treatment within 6 months of treatment initiation. Conclusions: This study suggests that a considerable proportion of pediatric patients with MS remain untreated within 1 year of diagnosis. Patients most commonly initiated injectables as their first DMT. Overall, therapy failed early in approximately one in three patients. Thus, the study warrants urgency in treating these patients with currently approved treatment options. Int J MS Care. 2021;23:101-105.
AB - Background: The current landscape and treatment patterns of disease-modifying therapy (DMT) use in pediatric patients with multiple sclerosis (MS) are not yet well understood. This study examined DMT utilization and treatment patterns in pediatric patients newly diagnosed as having MS. Methods: Pediatric patients (<18 years old) with two MS diagnosis claims from January 1, 2010, to December 31, 2016, were identified from the MarketScan Commercial Database. The index date was defined as the date of first MS diagnosis, and patients were followed up for 1 year post-index date. Outcomes evaluated included percentage of patients who initiated treatment after MS diagnosis, different DMTs initiated, treatment discontinuation, and switching treatment during follow-up. Results: Of 182,057 patients newly diagnosed as having MS, 288 pediatric patients (mean age, 14 years; 61% female) were identified. Within the first year of diagnosis, 188 patients (65.3%) did not receive any DMT. The most common first-initiated treatments were interferons and glatiramer acetate (83%), but 28% of patients switched or discontinued from first-initiated treatment within 6 months of treatment initiation. Conclusions: This study suggests that a considerable proportion of pediatric patients with MS remain untreated within 1 year of diagnosis. Patients most commonly initiated injectables as their first DMT. Overall, therapy failed early in approximately one in three patients. Thus, the study warrants urgency in treating these patients with currently approved treatment options. Int J MS Care. 2021;23:101-105.
UR - http://www.scopus.com/inward/record.url?scp=85106166675&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106166675&partnerID=8YFLogxK
U2 - 10.7224/1537-2073.2019-095
DO - 10.7224/1537-2073.2019-095
M3 - Article
C2 - 34177381
AN - SCOPUS:85106166675
SN - 1537-2073
VL - 23
SP - 101
EP - 105
JO - International Journal of MS Care
JF - International Journal of MS Care
IS - 3
ER -